Impact of Maintenance Therapy for Patients with Non-small Cell Lung Cancer in a Real-world Setting.
The purpose of this study was to explore the role of maintenance therapy for patients with advanced non-small cell lung cancer (NSCLC) in a real-world setting.



This was a prospective observational cohort multicenter study. Eligible patients were observed from initiation of first-line platinum-based chemotherapy until final follow-up.



Between 2010 and 2011, a total of 864 patients were enrolled in this study. The primary study population was 396 patients who had progressive disease during observation after first-line chemotherapy without maintenance. Of these, 113 patients (29%) did not receive second-line therapy. In contrast, only 18% of patients who had progressive disease during maintenance therapy missed second-line therapy. Overall survival of patients without maintenance who received second-line therapy was similar to that of those who received maintenance, but no second-line therapy.



Maintenance therapy for patients with advanced NSCLC might be an appropriate strategy to maximize the chance of receiving more active therapy.
Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan kyoh@east.ncc.go.jp.
Kiyotaka
K
Yoh
Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Yasushi
Y
Goto
Department of Breast and Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Yoichi
Y
Naito
Department of Respiratory Medicine, Respiratory Center, Toranomon Hospital, Tokyo, Japan.
Kazuma
K
Kishi
Department of Thoracic Disease, Tsuboi Cancer Center Hospital, Koriyama, Japan.
Kiyoshi
K
Mori
Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
Katsuyuki
K
Hotta
Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
Yukio
Y
Hosomi
Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan.
Kazuhiko
K
Yamada
Division of Respirology, NTT Medical Center Tokyo, Tokyo, Japan.
Chiharu
C
Tanai
Department of Respiratory Medicine, National Hospital Organization Nishigunma Hospital, Gunma, Japan.
Yoshio
Y
Tomizawa
Department of Palliative Medicine, Tohoku University School of Medicine, Sendai, Japan.
Akira
A
Inoue
Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Yoshinori
Y
Hasegawa
Department of Thoracic Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Makoto
M
Nishio
Department of Integrated Science and Engineering for Sustainable Society, Chuo University, Tokyo, Japan.
Yasuo
Y
Ohashi
Department of Medical Oncology, Japanese Red Cross Medical Center, Tokyo, Japan.
Hideo
H
Kunitoh
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000068258:Bevacizumab / Q000008:administration & dosage; D016190:Carboplatin / Q000008:administration & dosage*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality; D002945:Cisplatin / Q000008:administration & dosage*; D018450:Disease Progression; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009944:Organoplatinum Compounds / Q000008:administration & dosage*; D017239:Paclitaxel / Q000008:administration & dosage; D000068437:Pemetrexed / Q000008:administration & dosage; D011446:Prospective Studies; D012107:Research Design; D016896:Treatment Outcome
D009944:Organoplatinum Compounds; D000068437:Pemetrexed; D000068258:Bevacizumab; C053989:nedaplatin; D016190:Carboplatin; D017239:Paclitaxel; D002945:Cisplatin
Non-small cell lung cancer; maintenance therapy; platinum-based chemotherapy; second-line therapy